Abstract Details

Title Resting State Network Functional Connectivity Abnormalities in Systemic Lupus Erythematosus: Correlations with Neuropsychological and Neuropsychiatric Variables

Topic Multiple Sclerosis

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-055

Objective To investigate modifications of resting state (RS) functional connectivity (FC) in patients with systemic lupus erythematosus (SLE) and their correlations with neuropsychiatric involvement.

Background Neuropsychiatric manifestations, including cognitive impairment and depression, are highly prevalent in SLE-patients, but their neural substrates still have to be elucidated.

Design/Methods Thirty-two SLE-patients and 32 age- and sex-matched healthy controls (HC) underwent brain 3T dual-echo, 3D-T1 and RS fMRI acquisition. A neuropsychological and neuropsychiatric assessment was performed for all SLE-patients. Independent component analysis was used to derive the main large-scale cognitive functional networks. Between-group comparisons and correlations between RS FC abnormalities, neuropsychological and structural brain damage measures were performed.

Results Compared to HC, SLE-patients exhibited increased RS FC in the left middle cingulate cortex and decreased RS FC in the left precuneus within the default mode network (DMN), increased RS FC in the left cerebellar crus I and decreased RS FC in the left angular gyrus (L-AG) within the working-memory networks (WMNs) and decreased RS FC in the right middle frontal gyrus within the executive control network. Compared to cognitively preserved (n=22), cognitively impaired SLE-patients (n=10) showed increased RS FC in the left cerebellar crus I within WMNs. Compared to non-depressed (n=21), depressed SLE-patients (n=11) showed decreased FC in the L-AG within WMNs. In SLE-patients, RS FC abnormalities were correlated with worse memory and executive functions and T2 lesion volumes (r from -0.48 to 0.42, p from 0.001 to 0.04).

Conclusions Significant RS FC alterations in relevant cognitive functional networks occur in SLE-patients, are more pronounced in SLE-patients with cognitive impairment and depression and are correlated with neuropsychological variables and measures of structural damage. The assessment of RS FC might contribute to improve our understanding of the heterogeneous manifestations of SLE.

Authors/Disclosures
PRESENTER	No disclosure on file
Maria A. Rocca (Neuroimaging Research Unit)	Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Paolo Preziosa (Ospedale San Raffaele)	Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb . Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
	No disclosure on file
	No disclosure on file
Gianna Carla Riccitelli (San Raffaele)	No disclosure on file
	No disclosure on file
Paola Valsasina	Paola Valsasina has nothing to disclose.
	No disclosure on file
	No disclosure on file
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit)	Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.

��ɫ��

��ɫ��